Intrathecal liposomal cytarabine and leptomeningeal medulloblastoma relapse: A valuable therapeutic option

Angela Mastronuzzi, Francesca Del Bufalo, Anna Iacono, Domitilla Elena Secco, Annalisa Serra, Giovanna Stefania Colafati, Maria Antonietta De Ioris, Tiziana Corsetti

Research output: Contribution to journalArticle

Abstract

Background: Relapsed medulloblastoma (MB) is a highly lethal disease, requiring for new effective treatment strategies. Intrathecal (IT) therapy both for de novo or relapsed brain tumors with meningeal metastasis is rarely used in first line and relapse protocols. Patients and Methods: We report on three cases of children with relapsed MB treated with IT liposomal cytarabine administered after mild sedation every 15 days. Results: The treatment was well-tolerated in all patients, achieving a prolonged progression-free survival (4- 11 months) with a good quality of life. Conclusion: This experience suggests the need for a phase II trial in brain embryonal tumors with leptomeningeal metastasis to better evaluate the efficacy of IT liposomal cytarabine.

Original languageEnglish
Pages (from-to)3515-3518
Number of pages4
JournalAnticancer Research
Volume33
Issue number8
Publication statusPublished - Aug 2013

Keywords

  • Brain tumor
  • Case series
  • Intrathecal
  • Liposomal cytarabine
  • Medulloblastoma
  • Relapse/progression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Intrathecal liposomal cytarabine and leptomeningeal medulloblastoma relapse: A valuable therapeutic option'. Together they form a unique fingerprint.

  • Cite this